CABALETTA BIO, INC. Operating Expenses
CABALETTA BIO, INC. (CABA) reported Operating Expenses of $52.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- CABALETTA BIO, INC. operating expenses for the quarter ending 2026-06-30 was $52.02M, a 13.32% increase year-over-year.
- CABALETTA BIO, INC. operating expenses for the quarter ending 2026-03-31 was $44.30M, a 19.28% increase year-over-year.
- CABALETTA BIO, INC. operating expenses for the quarter ending 2025-12-31 was $42.61M, a 26.12% increase year-over-year.
- CABALETTA BIO, INC. operating expenses for the quarter ending 2025-09-30 was $46.59M, a 40.98% increase year-over-year.
- CABALETTA BIO, INC. operating expenses for fiscal 2025 was $172.24M, a 37.64% increase from fiscal 2024.
- CABALETTA BIO, INC. operating expenses for fiscal 2024 was $125.14M, a 67.61% increase from fiscal 2023.
- CABALETTA BIO, INC. operating expenses for fiscal 2023 was $74.66M, a 37.90% increase from fiscal 2022.
- CABALETTA BIO, INC. operating expenses for fiscal 2022 was $54.14M, a 16.90% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $52.02M 10-Q · filed 2026-08-13 | $96.32M 10-Q · filed 2026-08-13 | $138.93M derived: sum of 3 quarters · filed 2026-08-13 | $185.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $44.30M 10-Q · filed 2026-05-14 | $86.91M derived: sum of 2 quarters · filed 2026-05-14 | $133.50M derived: sum of 3 quarters · filed 2026-05-14 | $179.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $42.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $89.20M derived: sum of 2 quarters · filed 2026-03-23 | $135.10M derived: sum of 3 quarters · filed 2026-08-13 | $172.24M 10-K · filed 2026-03-23 |
| 2025-09-30 | $46.59M 10-Q · filed 2025-11-10 | $92.49M derived: sum of 2 quarters · filed 2026-08-13 | $129.63M 10-Q · filed 2025-11-10 | $163.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $45.91M 10-Q · filed 2026-08-13 | $83.04M 10-Q · filed 2026-08-13 | $116.83M derived: sum of 3 quarters · filed 2026-08-13 | $149.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $37.14M 10-Q · filed 2026-05-14 | $70.92M derived: sum of 2 quarters · filed 2026-05-14 | $103.97M derived: sum of 3 quarters · filed 2026-05-14 | $134.25M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $33.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $66.83M derived: sum of 2 quarters · filed 2026-03-23 | $97.11M derived: sum of 3 quarters · filed 2026-03-23 | $125.14M 10-K · filed 2026-03-23 |
| 2024-09-30 | $33.05M 10-Q · filed 2025-11-10 | $63.33M derived: sum of 2 quarters · filed 2025-11-10 | $91.36M 10-Q · filed 2025-11-10 | $114.50M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $30.28M 10-Q · filed 2025-08-07 | $58.31M 10-Q · filed 2025-08-07 | $81.46M derived: sum of 3 quarters · filed 2025-08-07 | $100.12M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $28.03M 10-Q · filed 2025-05-15 | $51.18M derived: sum of 2 quarters · filed 2025-05-15 | $69.84M derived: sum of 3 quarters · filed 2025-05-15 | $85.73M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $23.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $41.81M derived: sum of 2 quarters · filed 2025-03-31 | $57.70M derived: sum of 3 quarters · filed 2025-03-31 | $74.66M 10-K · filed 2025-03-31 |
| 2023-09-30 | $18.67M 10-Q · filed 2024-11-14 | $34.56M derived: sum of 2 quarters · filed 2024-11-14 | $51.51M 10-Q · filed 2024-11-14 | $67.82M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $15.89M 10-Q · filed 2024-08-08 | $32.85M 10-Q · filed 2024-08-08 | $49.15M derived: sum of 3 quarters · filed 2024-08-08 | $60.93M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $16.96M 10-Q · filed 2024-05-15 | $33.26M derived: sum of 2 quarters · filed 2024-05-15 | $45.04M derived: sum of 3 quarters · filed 2024-05-15 | $58.10M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $16.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $28.08M derived: sum of 2 quarters · filed 2024-03-21 | $41.14M derived: sum of 3 quarters · filed 2024-03-21 | $54.14M 10-K · filed 2024-03-21 |
| 2022-09-30 | $11.78M 10-Q · filed 2023-11-09 | $24.84M derived: sum of 2 quarters · filed 2023-11-09 | $37.84M 10-Q · filed 2023-11-09 | $51.73M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $13.06M 10-Q · filed 2023-08-10 | $26.06M 10-Q · filed 2023-08-10 | $39.95M derived: sum of 3 quarters · filed 2023-08-10 | $51.52M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $13.00M 10-Q · filed 2023-05-11 | $26.89M derived: sum of 2 quarters · filed 2023-05-11 | $38.45M derived: sum of 3 quarters · filed 2023-05-11 | $49.60M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $13.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $25.46M derived: sum of 2 quarters · filed 2023-03-16 | $36.60M derived: sum of 3 quarters · filed 2023-03-16 | $46.31M 10-K · filed 2023-03-16 |
| 2021-09-30 | $11.56M 10-Q · filed 2022-11-10 | $22.71M derived: sum of 2 quarters · filed 2022-11-10 | $32.42M 10-Q · filed 2022-11-10 | $41.75M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $11.14M 10-Q · filed 2022-08-11 | $20.86M 10-Q · filed 2022-08-11 | $30.19M derived: sum of 3 quarters · filed 2022-08-11 | $38.60M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $9.71M 10-Q · filed 2022-05-12 | $19.04M derived: sum of 2 quarters · filed 2022-05-12 | $27.46M derived: sum of 3 quarters · filed 2022-05-12 | $35.65M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $17.75M derived: sum of 2 quarters · filed 2022-03-17 | $25.94M derived: sum of 3 quarters · filed 2022-03-17 | $33.83M 10-K · filed 2022-03-17 |
| 2020-09-30 | $8.42M 10-Q · filed 2021-11-01 | $16.61M derived: sum of 2 quarters · filed 2021-11-01 | $24.50M 10-Q · filed 2021-11-01 | $30.36M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $8.19M 10-Q · filed 2021-08-05 | $16.09M 10-Q · filed 2021-08-05 | $21.95M derived: sum of 3 quarters · filed 2021-08-05 | $26.98M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $7.89M 10-Q · filed 2021-05-03 | $13.76M derived: sum of 2 quarters · filed 2021-05-03 | $18.79M derived: sum of 3 quarters · filed 2021-05-03 | $22.59M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $10.89M derived: sum of 2 quarters · filed 2021-03-16 | $14.69M derived: sum of 3 quarters · filed 2021-03-16 | $18.68M 10-K · filed 2021-03-16 |
| 2019-09-30 | $5.03M 10-Q · filed 2020-11-10 | $8.83M derived: sum of 2 quarters · filed 2020-11-10 | $12.82M 10-Q · filed 2020-11-10 | $14.89M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $3.80M 10-Q · filed 2020-08-06 | $7.79M 10-Q · filed 2020-08-06 | $9.86M derived: sum of 3 quarters · filed 2020-08-06 | $12.94M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $3.99M 10-Q · filed 2020-05-12 | $6.05M derived: sum of 2 quarters · filed 2020-05-12 | $9.13M derived: sum of 3 quarters · filed 2020-05-12 | |
| 2018-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $5.14M derived: sum of 2 quarters · filed 2020-03-30 | $6.19M 10-K · filed 2020-03-30 | |
| 2018-09-30 | $3.08M 10-Q · filed 2019-12-05 | $4.13M 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |